Tag: Rare diseases
Celgene, Acceleron bag Reblozyl FDA approval for anemia in beta thalassemia
Reblozyl FDA approval : Celgene and Acceleron Pharma have bagged approval from the US Food and Drug Administration (FDA) for Reblozyl (luspatercept-aamt) for the treatment ... Read More
Alexion to acquire Achillion to strengthen rare diseases portfolio
Alexion acquisition of Achillion : Alexion Pharmaceuticals has agreed to acquire rival US pharma company Achillion Pharmaceuticals for about $930 million in an all-cash deal ... Read More
Pfizer wraps up $810m acquisition of Swiss biotech company Therachon
Pfizer acquisition of Therachon : US pharma giant Pfizer has completed its previously announced acquisition of Swiss biotech company Therachon, which is focused on rare ... Read More
Alexion to acquire Boston-based Syntimmune in $1.2bn deal
Alexion acquisition of Syntimmune : US pharma company Alexion Pharmaceuticals has signed a deal of around $1.2 billion to acquire Syntimmune, a Boston-based clinical-stage biotech ... Read More